| Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis DG Ribaldone, R Pellicano, M Vernero, GP Caviglia, GM Saracco, ... Scandinavian Journal of Gastroenterology 54 (4), 407-413, 2019 | 55 | 2019 |
| The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study M Vernero, F De Blasio, DG Ribaldone, E Bugianesi, R Pellicano, ... Journal of clinical medicine 9 (12), 3941, 2020 | 50 | 2020 |
| Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons GE Tontini, A Rimondi, M Vernero, H Neumann, M Vecchi, C Bezzio, ... Therapeutic advances in gastroenterology 14, 17562848211017730, 2021 | 36 | 2021 |
| Pitfalls in the diagnosis of coeliac disease and Gluten-Related disorders A Schiepatti, J Savioli, M Vernero, F Borrelli de Andreis, L Perfetti, ... Nutrients 12 (6), 1711, 2020 | 36 | 2020 |
| Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study DG Ribaldone, GP Caviglia, R Pellicano, M Vernero, GM Saracco, ... Revista espanola de enfermedades digestivas 112 (3), 195-200, 2020 | 34 | 2020 |
| New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor secukinumab: a case series M Vernero, M Astegiano, DG Ribaldone Official journal of the American College of Gastroenterology| ACG 114 (1 …, 2019 | 28 | 2019 |
| Switching from biosimilar to biosimilar adalimumab, including multiple switching, in Crohn’s disease: a prospective study DG Ribaldone, E Tribocco, C Rosso, A Armandi, M Vernero, E Bugianesi, ... Journal of Clinical Medicine 10 (15), 3387, 2021 | 26 | 2021 |
| Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations C Bezzio, C Della Corte, M Vernero, I Di Luna, G Manes, S Saibeni Therapeutic Advances in Gastroenterology 15, 17562848221115312, 2022 | 24 | 2022 |
| Inflammatory bowel disease nurse—practical messages C Rosso, AA Aaron, A Armandi, GP Caviglia, M Vernero, GM Saracco, ... Nursing Reports 11 (2), 229-241, 2021 | 24 | 2021 |
| Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy DG Ribaldone, I Dileo, R Pellicano, A Resegotti, S Fagoonee, M Vernero, ... Irish Journal of Medical Science (1971-) 187, 385-392, 2018 | 20 | 2018 |
| Periodontitis prevalence and severity in inflammatory bowel disease: A case–control study G Baima, M Muwalla, G Testa, F Mazza, A Bebars, S Perotto, M Vernero, ... Journal of periodontology 94 (3), 313-322, 2023 | 19 | 2023 |
| Determinants and trends of adherence to a gluten-free diet in adult celiac patients on a long-term follow-up (2000–2020) A Schiepatti, S Maimaris, ML Nicolardi, E Alimenti, M Vernero, M Costetti, ... Clinical Gastroenterology and Hepatology 20 (4), e741-e749, 2022 | 19 | 2022 |
| Crosstalk between irisin levels, liver fibrogenesis and liver damage in non-obese, non-diabetic individuals with non-alcoholic fatty liver disease A Armandi, C Rosso, A Nicolosi, GP Caviglia, ML Abate, A Olivero, ... Journal of Clinical Medicine 11 (3), 635, 2022 | 16 | 2022 |
| The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets DG Ribaldone, M Vernero, GM Saracco, R Pellicano, F Finocchiaro, ... Scandinavian journal of gastroenterology 53 (2), 141-146, 2018 | 14 | 2018 |
| Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in … GP Caviglia, F De Blasio, M Vernero, A Armandi, C Rosso, GM Saracco, ... Journal of Clinical Medicine 10 (21), 4961, 2021 | 12 | 2021 |
| Insights into the role of gastrointestinal ultrasound in ulcerative colitis C Bezzio, M Vernero, DG Ribaldone, G Manes, S Saibeni Therapeutic Advances in Gastroenterology 14, 17562848211051456, 2021 | 12 | 2021 |
| Oral iron supplementation with Feralgine® in inflammatory bowel disease: A retrospective observational study MG e Dietologica Minerva Gastroenterologica e Dietologica, 2019 | 12 | 2019 |
| Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS‐CoV‐2 infection: an IG‐IBD study C Bezzio, A Armuzzi, F Furfaro, S Ardizzone, M Milla, S Carparelli, ... Alimentary Pharmacology & Therapeutics 54 (11-12), 1432-1441, 2021 | 11 | 2021 |
| Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study FS Macaluso, M Principi, F Facciotti, A Contaldo, A Todeschini, S Saibeni, ... Digestive and Liver Disease 55 (2), 154-159, 2023 | 10 | 2023 |
| Dual‐targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn’s disease M Vernero, DG Ribaldone, C Cariti, S Ribero, S Susca, M Astegiano, ... The Journal of Dermatology 47 (6), e216-e217, 2020 | 9 | 2020 |
